Influence of adjuvants in inducing immune responses to different epitopes included in a multiepitope, multivalent, multistage Plasmodium falciparum candidate vaccine (FALVAC-1) in outbred mice

Experimental Parasitology

Volumn 101, Issue 1, 2002, Pages 3-12

  Rafi Janajreh, Asimah ^a   Tongren, Jon Eric ^a   Kensil, Charlotte ^b   Hackett, Craig ^c   Candal, Francisco ^a   Lal, Altaf ^a   Udhayakumar, Venkatachalam ^a  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b Antigenics Inc   (United States)

^c Protein Sciences Corp   (United States)

Author keywords

Adjuvant; Malaria; Plasmodium falciparum; Vaccine

Indexed keywords

ADJUVANT P1005; ALUMINUM HYDROXIDE; ANTIGEN; EPITOPE; FALVAC 1; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN G3; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYNUCLEOTIDE; PROTOZOAL VACCINE; QS 21; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG FORMULATION; FEMALE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOREACTIVITY; LYMPHOCYTE PROLIFERATION; MALARIA; MOUSE; NONHUMAN; OUTBRED STRAIN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SPOROZOITE;

ADJUVANTS, IMMUNOLOGIC; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CYTOKINES; EPITOPES; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; IMMUNE SERA; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MALARIA VACCINES; MICE; MOLECULAR SEQUENCE DATA; PLASMODIUM FALCIPARUM; T-LYMPHOCYTES;

PLASMODIUM FALCIPARUM;

EID: 0036591293     PISSN: 00144894     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-4894(02)00029-2     Document Type: Article

References (23)

1. Coughlin R.T., Fattom A., Chu C., White A.C., Winston S. Adjuvant activity of QS-21 for experimental E. coli 018 polysaccharide vaccines. Vaccine. 13:1995;17-21.
2. D'Alessandro U., Leach A., Drakeley C.J., Bennett S., Olaleye B.O., Fegan G.W., Jawara M., Langerock P., George M.O., Targett G.A.et al. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet. 346:1995;462-467.
3. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., Krieg A.M., Weeratna R. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. Journal of Immunology. 160:1998;870-876.
4. de Oliveira G.A., Clavijo P., Nussenzweig R.S., Nardin E.H. Immunogeicity of an alum-adsorbed synthetic multiple-antigen peptide based on B- and T-cell epitopes of the Plasmodium falciparum CS protein: possible vaccine application. Vaccine. 12:1994;1012-1017.
5. Gilbert S.C., Plebanski M., Harris S.J., Allsopp C.E., Thomas R., Layton G.T., Hill A.V. A protein particle vaccine containing multiple malaria epitopes. Nature Biotechnology. 15:1997;1280-1284.
6. Hancock G.E., Speelman D.J., Frenchick P.J., Mineo-Kuhn M.M., Baggs R.B., Hahn D.J. Formulation of the purified fusion protein of respiratory syncytial virus with thesaponinQS-21 induces protective immune responses in Balb/c mice that are similar to those generated by experimental infection. Vaccine. 13:1995;391-400.
7. Hunter R.L., Lal A.A. Copolymer adjuvants in malaria vaccine development. American Journal Tropical Medicine and Hygeine. 50:1994;52-58.
8. Hunter R.L., McNicholl J., Lal A.A. Mechanisms of action of nonionic block copolymer adjuvants. AIDS Research and Human Retroviruses. 10:1994;S95-S98.
9. Kensil C.R., Patel U., Lennick M., Marciani D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria Molina cortex. Journal of Immunology. 146:1991;431-437.
10. Kensil C.R., Wu J.-W., Soltysik S. Structural and immunologic characterization of the vaccine adjuvant QS-21. Powell M.F., Newman M.J. Vaccine Design: The Subunit and Adjuvant Approach. 1995;525-541 Plenum, New York.
11. Lipford G.B., Bauer M., Blank C., Reiter R., Wagner H., Heeg K. CpG-containing synthetic oligonucleotides promote B and cytotoxic T cell responses to protein antigen: a new class of vaccine adjuvants. European Journal of Immunology. 27:1997;2340-2344.
12. Ma J., Bulger P.A., Davis D.R., Perilli-Palmer B., Bedore D.A., Kensil C.R., Young E.M., Hung C.H., Seals J.R., Pavia C.S.et al. Impact of the saponin adjuvant QS-21 and aluminium hydroxide on the immunogenicity of recombinant OspA and OspB of Borrelia burgdorferi. Vaccine. 12:1994;925-932.
13. Messina J.P., Gilkeson G.S., Pisetsky D.S. Stimulation of in vitro murine lymphocyte proliferation by bacterial DNA. Journal of Immunology. 147:1991;1759-1764.
14. Nosten F., Luxemburger C., Kyle D.E., Ballou W.R., Wittes J., Wah E., Chongsuphajaisiddhi T., Gordon D.M., White N.J., Sadoff J.C., Heppner D.G. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in northwestern Thailand. Shoklo SPf66 Malaria Vaccine Trial Group. Lancet. 348(9029):1996;701-707.
15. Ockenhouse C.F., Sun P.F., Lanar D.E., Wellde B.T., Hall B.T., Kester K., Stoute J.A., Magill A., Krzych U., Farley L., Wirtz R.A., Sadoff J.C., Kaslow D.C., Kumar S., Church L.W., Crutcher J.M., Wizel B., Hoffman S., Lalvani A., Hill A.V., Tine J.A., Guito K.P., de Taisne C., Anders R., Ballou W.R.et al. Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Journal of Infectious Diseases. 177:1998;1664-1673.
16. Patarroyo M.E., Amador R., Clavijo P., Moreno A., Guzman F., Romero P., Tascon R., Franco A., Murillo L.A., Ponton G.et al. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature. 332:1988;158-161.
17. Shi Y.P., Hasnain S.E., Sacci J.B., Holloway B.P., Fujioka H., Kumar N., Wohlhueter R., Hoffman S.L., Collins W.E., Lal A.A. Immunogenicity and in vitro protective efficacy of a recombinant multistage Plasmodium falciparum candidate vaccine. Proceedings of the National Academy of Sciences USA. 96:1999;1615-1620.
18. Shi Y.P., Das P., Holloway B., Udhayakumar V., Tongren I.E., Candal R., Biswas S., Ahmad R., Hasnain S.E., Lal A.A. Development, expression, and murine testing of a multistage Plasmodium falciparum malaria vaccine candidate. Vaccine. 18:2000;2902-2914.
19. Sparwasser T., Koch E.S., Vabulas R.M., Heeg K., Lipford G.B., Ellwart J.W., Wagner H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. European Journal of Immunology. 28:1998;2045-2054.
20. Stoute J.A., Slaoui M., Heppner D.G., Momin P., Kester K.E., Desmons P., Wellde B.T., Garcon N., Krzych U., March M. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria RTS,S Malaria Vaccine Evaluation Group. New England Journal of Medicine. 336:1997;86-91.
21. Stoute J.A., Kester K.E., Krzych U., Wellde B.T., Hall T., White K., Glenn G., Ockenhouse C.R., Garcon N., Schwenk R., Lanar D.E., Sun P., Momin P., Wirtz R.A., Golenda C., Slaoui M., Wortmann G., Holland C., Dowler M., Cohen J., Ballou W.R. Long-term efficacy and immune responses following immunization with the RTS,S malaria vaccine. Journal of Infectious Diseases. 178:1998;1139-1144.
22. ten Hagen T.L.M., Sulzer A.J., Kidd M.R., Lal A.A., Hunter R.L. Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood stage Plasmodium yoelii vaccines. Journal of Immunology. 151:1993;7077-7085.
23. World Health Organization, 1989. Weekly Epidemiology Research, pp. 241-247.